The consumer health industry is changing. Companies are separating from their pharmaceutical parents and brands are shifting from therapeutic solutions to preventative health and wellness options.
These shifts bring a number of challenges for OTC firms, notes AdverCheck managing director James Walmsley in the second part of his discussion with HBW Insight on the Over The Counter podcast. (Listen to Part 1 here).
For example, it is much more difficult to get science-backed claims for food supplements approved, he points out.
With firms now also becoming standalone consumer health entities, there is no longer a direct pipeline of off-patent prescription medicines available for Rx-to-OTC switch, he observes.
We may, therefore, see a new generation of switch-focused self-care companies and partnerships emerging.
Timeline
2:00 – The changing consumer health industry
5:30 – Are CHC companies well placed for prevention?
10:15 – Have the promises of Brexit been realized?
13:00 – The challenge of Rx-to-OTC switch today
17:20 – The rise of switch specialists
19:30 – Will the UK be a switch leader?
20:30 – How has AdverCheck changed with industry?
Guest Bio
James is a pharmaceutical physician with 20 years industry experience in medical affairs and advertising review within the consumer healthcare sector. After working at Boots, James served as UK medical director for both Pfizer Consumer Healthcare and Johnson and Johnson, leading the team responsible for advertising review.
AdverCheck Ltd was launched in 2022 by James and Lucy Rochford to provide specialist outsourced copy review and related services to the consumer healthcare sector and has worked with many major UK consumer healthcare companies.
